.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Novartis
Fuji
Chinese Patent Office
Harvard Business School
Cerilliant
US Army
Express Scripts
Accenture
Baxter

Generated: September 21, 2017

DrugPatentWatch Database Preview

PATANASE Drug Profile

« Back to Dashboard

What is the patent landscape for Patanase, and what generic Patanase alternatives are available?

Patanase is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

Summary for Tradename: PATANASE

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list4
Bulk Api Vendors: see list38
Clinical Trials: see list3
Patent Applications: see list1,758
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PATANASE at DailyMed

Pharmacology for Tradename: PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
PATANASE
olopatadine hydrochloride
SPRAY, METERED;NASAL021861-001Apr 15, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
PATANASE
olopatadine hydrochloride
SPRAY, METERED;NASAL021861-001Apr 15, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PATANASE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
PATANASE
olopatadine hydrochloride
SPRAY, METERED;NASAL021861-001Apr 15, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PATANASE

Drugname Dosage Strength RLD Submissiondate
olopatadine hydrochlorideNasal Spray0.665 mg/ SprayPatanase6/29/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
Baxter
Fish and Richardson
Medtronic
QuintilesIMS
Farmers Insurance
Dow
Accenture
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot